Research Overview

Dr. Kourembanas’ research program investigates the molecular and cellular basis of lung inflammation and the immune pathways modulating lung injury, tissue remodeling and repair in the developing lung. Using genetically modified mouse models, her group discovered that inflammation plays a critical role in the development of hypoxic pulmonary hypertension that has become a major focus of study for the lung vascular biology field exploring mechanisms of disease and therapeutic strategies targeting lung inflammation. A complementary active area of research in the lab is the study of stem cell-based therapies focusing on the biology and application of mesenchymal stem cell extracellular vesicles/exosomes (MEx) as vectors of intercellular signaling and potent immune modulators. Of note, her group was first to demonstrate the effect of MEx on preventing and reversing pulmonary hypertension and neonatal hyperoxic lung injury in experimental models, paving the way for future cell-free regenerative approaches for the treatment of important diseases of the newborn infant resulting from oxidant stress, inflammation, cell death, and dysregulated tissue repair.

Dr. Kourembanas serves as Program Director of a NIH-funded T32 program training physician-scientists in neonatal-perinatal medicine since 2003. She has served as PI on several previous and current NIH-funded grants including a Specialized Center of Research (SCOR) program on developmental lung injury and repair, and has led several collaborative basic and translational studies, as well as a clinical trial of inhaled nitric oxide for neonates with respiratory failure that have contributed new knowledge to this field.

Research Background

Stella Kourembanas is the Clement A. Smith Professor of Pediatrics at Harvard Medical School and Chief of the Division of Newborn Medicine at Boston Children’s Hospital. Dr. Kourembanas received her M.D. from New York University Medical Center and completed her residency in Pediatrics at Massachusetts General Hospital, Boston. She subsequently completed a Fellowship in Neonatal-Perinatal Medicine in the Joint Program of Neonatology of Harvard Medical School and was appointed to the faculty of the same Program. She has held the Clement A. Smith Professorship since 2005 and was appointed Chief of Neonatology at Boston Children’s Hospital and Academic Chair of the Harvard Neonatal-Perinatal Medicine Program that same year.

She is an internationally recognized expert on the biology of hypoxia and the investigation of stem cell-based therapies for the treatment of developmental and vascular diseases of the lung. She is an elected member to the American Society for Clinical investigation, the Pediatric Academic Societies, and the Society of Perinatal Research. She has given several State-of-the-Art, Keynote lectures, and named lectureships on her research discoveries at national and international symposia and has served as standing member and chair of NIH study sections and other Foundations including the Parker B. Francis Fellowship Program and the Hood Foundation. She has also been the recipient of two teaching awards from the Harvard programs for excellence in teaching and for mentoring the career development of Pediatric Residents (Janeway Award) and Neonatology Fellows (Bernfield Award). In particular, the Charles A. Janeway Teaching Award is considered the most prestigious distinction for teaching at Boston Children’s Hospital.

Education

Undergraduate School

Barnard College
1978 New York NY

Medical School

New York University School of Medicine
1982 New York NY

Internship

Massachusetts General Hospital
1983 Boston MA

Residency

Massachusetts General Hospital
1984 Boston MA

Fellowship

Joint Program in Neonatology Harvard Medical School
1987 Boston MA

Publications

  1. Immunoregulatory Macrophages Modify Local Pulmonary Immunity and Ameliorate Hypoxic Pulmonary Hypertension. Arterioscler Thromb Vasc Biol. 2024 Dec; 44(12):e288-e303. View Abstract
  2. Mesenchymal stromal cell extracellular vesicles improve lung development in mechanically ventilated preterm lambs. Am J Physiol Lung Cell Mol Physiol. 2024 Jun 01; 326(6):L770-L785. View Abstract
  3. SOCS3 regulates pathological retinal angiogenesis through modulating SPP1 expression in microglia and macrophages. Mol Ther. 2024 May 01; 32(5):1425-1444. View Abstract
  4. Photoreceptors inhibit pathological retinal angiogenesis through transcriptional regulation of Adam17 via c-Fos. Angiogenesis. 2024 Aug; 27(3):379-395. View Abstract
  5. No Place Like Home: Improving the Transition From NICU to Home Through the NICU to Nursery Program. Adv Neonatal Care. 2024 Feb 01; 24(1):46-57. View Abstract
  6. Immunoregulatory macrophages modify local pulmonary immunity and ameliorate hypoxic-pulmonary hypertension. bioRxiv. 2023 Aug 02. View Abstract
  7. Pericytes Contribute to Flow-induced Pulmonary Hypertension. Am J Respir Cell Mol Biol. 2023 06; 68(6):705-708. View Abstract
  8. Harnessing the therapeutic potential of the stem cell secretome in neonatal diseases. Semin Perinatol. 2023 04; 47(3):151730. View Abstract
  9. Second International Pulmonary Hypertension/Heart Failure Symposium-Structural heart disease, right ventricular dysfunction, and stem cell therapy: The European Pediatric Pulmonary Vascular Disease Network. Pulm Circ. 2023 Jan; 13(1):e12175. View Abstract
  10. Mesenchymal Stromal/Stem Cell Extracellular Vesicles and Perinatal Injury: One Formula for Many Diseases. Stem Cells. 2022 11 29; 40(11):991-1007. View Abstract
  11. Diagnosis and management of pulmonary hypertension in infants with bronchopulmonary dysplasia. Semin Fetal Neonatal Med. 2022 08; 27(4):101351. View Abstract
  12. Urine Proteomics for Noninvasive Monitoring of Biomarkers in Bronchopulmonary Dysplasia. Neonatology. 2022; 119(2):193-203. View Abstract
  13. Antenatal Mesenchymal Stromal Cell Extracellular Vesicle Therapy Prevents Preeclamptic Lung Injury in Mice. Am J Respir Cell Mol Biol. 2022 01; 66(1):86-95. View Abstract
  14. Extracellular Vesicles Protect the Neonatal Lung from Hyperoxic Injury through the Epigenetic and Transcriptomic Reprogramming of Myeloid Cells. Am J Respir Crit Care Med. 2021 12 15; 204(12):1418-1432. View Abstract
  15. Antenatal mesenchymal stromal cell extracellular vesicle treatment preserves lung development in a model of bronchopulmonary dysplasia due to chorioamnionitis. Am J Physiol Lung Cell Mol Physiol. 2022 02 01; 322(2):L179-L190. View Abstract
  16. Intratracheal transplantation of trophoblast stem cells attenuates acute lung injury in mice. Stem Cell Res Ther. 2021 08 30; 12(1):487. View Abstract
  17. Mesenchymal stromal cell-derived syndecan-2 regulates the immune response during sepsis to foster bacterial clearance and resolution of inflammation. FEBS J. 2022 01; 289(2):417-435. View Abstract
  18. Acetazolamide Improves Right Ventricular Function and Metabolic Gene Dysregulation in Experimental Pulmonary Arterial Hypertension. Front Cardiovasc Med. 2021; 8:662870. View Abstract
  19. Mesenchymal Stromal Cell-Derived Extracellular Vesicles Restore Thymic Architecture and T Cell Function Disrupted by Neonatal Hyperoxia. Front Immunol. 2021; 12:640595. View Abstract
  20. Therapeutic Effects of Mesenchymal Stromal Cell-Derived Small Extracellular Vesicles in Oxygen-Induced Multi-Organ Disease: A Developmental Perspective. Front Cell Dev Biol. 2021; 9:647025. View Abstract
  21. Mesenchymal stromal cell-derived extracellular vesicle therapy prevents preeclamptic physiology through intrauterine immunomodulation†. Biol Reprod. 2021 02 11; 104(2):457-467. View Abstract
  22. Perinatal Hypoxia-Inducible Factor Stabilization Preserves Lung Alveolar and Vascular Growth in Experimental Bronchopulmonary Dysplasia. Am J Respir Crit Care Med. 2020 10 15; 202(8):1146-1158. View Abstract
  23. Gene and Stem Cell Therapies for Fetal Care: A Review. JAMA Pediatr. 2020 10 01; 174(10):985-991. View Abstract
  24. Mesenchymal stromal cell-derived small extracellular vesicles restore lung architecture and improve exercise capacity in a model of neonatal hyperoxia-induced lung injury. J Extracell Vesicles. 2020 Jul 13; 9(1):1790874. View Abstract
  25. Pulmonary hypertension in bronchopulmonary dysplasia. Pediatr Res. 2021 02; 89(3):446-455. View Abstract
  26. Echocardiographic markers of pulmonary hemodynamics and right ventricular hypertrophy in rat models of pulmonary hypertension. Pulm Circ. 2020 Apr-Jun; 10(2):2045894020910976. View Abstract
  27. Mesenchymal stromal cell exosomes prevent and revert experimental pulmonary fibrosis through modulation of monocyte phenotypes. JCI Insight. 2019 11 01; 4(21). View Abstract
  28. Heme oxygenase-1 dampens the macrophage sterile inflammasome response and regulates its components in the hypoxic lung. Am J Physiol Lung Cell Mol Physiol. 2020 01 01; 318(1):L125-L134. View Abstract
  29. Carbonic Anhydrase Inhibition Ameliorates Inflammation and Experimental Pulmonary Hypertension. Am J Respir Cell Mol Biol. 2019 10; 61(4):512-524. View Abstract
  30. Macrophage Immunomodulation: The Gatekeeper for Mesenchymal Stem Cell Derived-Exosomes in Pulmonary Arterial Hypertension? Int J Mol Sci. 2018 Aug 27; 19(9). View Abstract
  31. PPAR? agonist pioglitazone reverses pulmonary hypertension and prevents right heart failure via fatty acid oxidation. Sci Transl Med. 2018 04 25; 10(438). View Abstract
  32. Reply to Muraca et al.: Exosome Treatment of Bronchopulmonary Dysplasia: How Pure Should Your Exosome Preparation Be? Am J Respir Crit Care Med. 2018 04 01; 197(7):970. View Abstract
  33. Mesenchymal Stromal Cell Exosomes Ameliorate Experimental Bronchopulmonary Dysplasia and Restore Lung Function through Macrophage Immunomodulation. Am J Respir Crit Care Med. 2018 01 01; 197(1):104-116. View Abstract
  34. Impaired Pulmonary Arterial Vasoconstriction and Nitric Oxide-Mediated Relaxation Underlie Severe Pulmonary Hypertension in the Sugen-Hypoxia Rat Model. J Pharmacol Exp Ther. 2018 02; 364(2):258-274. View Abstract
  35. "Good things come in small packages": application of exosome-based therapeutics in neonatal lung injury. Pediatr Res. 2018 01; 83(1-2):298-307. View Abstract
  36. Toward Exosome-Based Therapeutics: Isolation, Heterogeneity, and Fit-for-Purpose Potency. Front Cardiovasc Med. 2017; 4:63. View Abstract
  37. Can We Cure Bronchopulmonary Dysplasia? J Pediatr. 2017 12; 191:12-14. View Abstract
  38. Therapeutic Applications of Extracellular Vesicles: Perspectives from Newborn Medicine. Methods Mol Biol. 2017; 1660:409-432. View Abstract
  39. Stem cell-based therapies for the newborn lung and brain: Possibilities and challenges. Semin Perinatol. 2016 Apr; 40(3):138-51. View Abstract
  40. Systemic Administration of Human Bone Marrow-Derived Mesenchymal Stromal Cell Extracellular Vesicles Ameliorates Aspergillus Hyphal Extract-Induced Allergic Airway Inflammation in Immunocompetent Mice. Stem Cells Transl Med. 2015 Nov; 4(11):1302-16. View Abstract
  41. The Sugen 5416/hypoxia mouse model of pulmonary hypertension revisited: long-term follow-up. Pulm Circ. 2014 Dec; 4(4):619-29. View Abstract
  42. Exosomes: vehicles of intercellular signaling, biomarkers, and vectors of cell therapy. Annu Rev Physiol. 2015; 77:13-27. View Abstract
  43. An Argonaute 2 switch regulates circulating miR-210 to coordinate hypoxic adaptation across cells. Biochim Biophys Acta. 2014 Nov; 1843(11):2528-42. View Abstract
  44. Expanding the pool of stem cell therapy for lung growth and repair. Circulation. 2014 May 27; 129(21):2091-3. View Abstract
  45. Stem cell-based therapy for newborn lung and brain injury: feasible, safe, and the next therapeutic breakthrough? J Pediatr. 2014 May; 164(5):954-6. View Abstract
  46. MSC microvesicles for the treatment of lung disease: a new paradigm for cell-free therapy. Antioxid Redox Signal. 2014 Nov 01; 21(13):1905-15. View Abstract
  47. Endothelial indoleamine 2,3-dioxygenase protects against development of pulmonary hypertension. Am J Respir Crit Care Med. 2013 Aug 15; 188(4):482-91. View Abstract
  48. Cell therapy for lung diseases. Report from an NIH-NHLBI workshop, November 13-14, 2012. Am J Respir Crit Care Med. 2013 Aug 01; 188(3):370-5. View Abstract
  49. Diffuse lung disease in children: summary of a scientific conference. Pediatr Pulmonol. 2014 Apr; 49(4):400-9. View Abstract
  50. Exosomes mediate the cytoprotective action of mesenchymal stromal cells on hypoxia-induced pulmonary hypertension. Circulation. 2012 Nov 27; 126(22):2601-11. View Abstract
  51. Perinatal stress, brain inflammation and risk of autism-review and proposal. BMC Pediatr. 2012 Jul 02; 12:89. View Abstract
  52. Mesenchymal stem cell-mediated reversal of bronchopulmonary dysplasia and associated pulmonary hypertension. Pulm Circ. 2012 Apr-Jun; 2(2):170-81. View Abstract
  53. Regenerative pulmonary medicine: potential and promise, pitfalls and challenges. Eur J Clin Invest. 2012 Aug; 42(8):900-13. View Abstract
  54. Bronchioalveolar stem cells increase after mesenchymal stromal cell treatment in a mouse model of bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol. 2012 May 01; 302(9):L829-37. View Abstract
  55. Vasculoprotective effects of heme oxygenase-1 in a murine model of hyperoxia-induced bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol. 2012 Apr 15; 302(8):L775-84. View Abstract
  56. Improved pulmonary vascular reactivity and decreased hypertrophic remodeling during nonhypercapnic acidosis in experimental pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2012 May 01; 302(9):L875-90. View Abstract
  57. Early macrophage recruitment and alternative activation are critical for the later development of hypoxia-induced pulmonary hypertension. Circulation. 2011 May 10; 123(18):1986-95. View Abstract
  58. Mesenchymal stromal cells expressing heme oxygenase-1 reverse pulmonary hypertension. Stem Cells. 2011 Jan; 29(1):99-107. View Abstract
  59. In-house neonatology: what are we waiting for? Am J Respir Crit Care Med. 2010 Sep 15; 182(6):728-9. View Abstract
  60. Bone marrow stromal cells attenuate lung injury in a murine model of neonatal chronic lung disease. Am J Respir Crit Care Med. 2009 Dec 01; 180(11):1122-30. View Abstract
  61. Divergent cardiopulmonary actions of heme oxygenase enzymatic products in chronic hypoxia. PLoS One. 2009 Jun 19; 4(6):e5978. View Abstract
  62. Mutation of murine adenylate kinase 7 underlies a primary ciliary dyskinesia phenotype. Am J Respir Cell Mol Biol. 2009 Mar; 40(3):305-13. View Abstract
  63. Absence of cyclooxygenase-2 exacerbates hypoxia-induced pulmonary hypertension and enhances contractility of vascular smooth muscle cells. Circulation. 2008 Apr 22; 117(16):2114-22. View Abstract
  64. Absence of COX-2 exacerbates hypoxia-induced pulmonary hypertension and enhances contractility of vascular smooth muscle cells. J Clin Invest. Submitted. 2007. View Abstract
  65. Hypoxia regulates bone morphogenetic protein signaling in vascular smooth muscle cells through CtBP-1. Circ. Res. 2006; 99:240-247. View Abstract
  66. Hypoxia regulates bone morphogenetic protein signaling through C-terminal-binding protein 1. Circ Res. 2006 Aug 04; 99(3):240-7. View Abstract
  67. Bone marrow derived mesenchymal stem cells expressing human heme oxygenase-1 (HO-1) reverse hypoxic pulmonary hypertension in HO-1 null mice. American Thoracic Society International Conference Proceedings. 2006; 3:A25. View Abstract
  68. Heme oxygenase-1 (HO-1) overexpression prevents fibrosis and iron deposition in developmental lung injury. American Thoracic Society International Conference Proceedings. 2006; 3:A254. View Abstract
  69. Exacerbation of hypoxia-induced pulmonary hypertension and vascular remodeling in COX-2 deficient mice. American Thoracic Society International Conference Proceedings. 2006; 3:A278. View Abstract
  70. Mechanisms of heme oxygenase-1-mediated cardiac and pulmonary vascular protection in chronic hypoxia: roles of carbon monoxide and bilirubin. Chest. 2005 Dec; 128(6 Suppl):578S-579S. View Abstract
  71. Pulmonary hypertension and right ventricular dysfunction in growth-restricted, extremely low birth weight neonates. J Perinatol. 2005 Jul; 25(7):495-9. View Abstract
  72. Extracellular acidosis induces heme oxygenase-1 expression in vascular smooth muscle cells. Am J Physiol Heart Circ Physiol. 2005 Jun; 288(6):H2647-52. View Abstract
  73. HO-1 mediated cardiac protection in chronic hypoxia: Role of carbon monoxide and bilirubin. 4th International HO Conference, Boston, MA. 2005. View Abstract
  74. Bone-marrow derived mesenchymal stem cells expressing human HO-1 reverse hypoxic pulmonary hypertension in HO-1 null mice. 4th International HO Conference, Boston, MA. 2005. View Abstract
  75. Heme Oxygenase-1 overexpression decreases alveolar remodeling and iron deposition in developmental lung injury. 4th International CO Conference, Boston, MA. 2005. View Abstract
  76. Hypoxia induces macrophage inflammatory protein-2 (MIP-2) gene expression in murine macrophages via NF-kappaB: the prominent role of p42/ p44 and PI3 kinase pathways. FASEB J. 2004 Jul; 18(10):1090-2. View Abstract
  77. Hypoxia suppresses bone morphogenetic protein mediated Id1 gene activation n human pulmonary artery smooth muscle cells. Am. J. Respir. Crit. Care Med. 2004; A510. View Abstract
  78. Mechanisms of HO-1 cytoprotection in hypoxic pulmonary hypertension. Pediatric Research. 2004; 55(4):A2683. View Abstract
  79. Shock. Manual of Neonatal Care(Cloherty JP, Eichenwald E, Stark AR, eds.). 2004; 181-185. View Abstract
  80. Effect of heme oxygenase-1 overexpression in two models of lung inflammation. Exp Biol Med (Maywood). 2003 May; 228(5):442-6. View Abstract
  81. Regulation of heme oxygenase-1 (HO-1) gene expression in vascular smooth muscle cells by extracellular acidosis. Pediatric Research. 2003; 53(4):A3220. View Abstract
  82. Hypoxia and carbon monoxide in the vasculature. Antioxid Redox Signal. 2002 Apr; 4(2):291-9. View Abstract
  83. Response of the developing lung to injury (Haddad GG, Abman S, Chernik V, eds.). Basic Mechanisms of Pediatric Respiratory Disease. 2002; 102-123. View Abstract
  84. Regulation of macrophage inflammatory protein-2 (MIP-2) gene expression by hypoxia. Am. J. Respir. Crit. Care Med. 2002; 165(8):A546. View Abstract
  85. Targeted expression of heme oxygenase-1 and pulmonary responses to hypoxia. Heme Oxygenase in Biology and Medicine. 2002; 193-204. View Abstract
  86. Mechanisms of telomerase induction during vascular smooth muscle cell proliferation. Circ Res. 2001 Aug 03; 89(3):237-43. View Abstract
  87. Targeted expression of heme oxygenase-1 prevents the pulmonary inflammatory and vascular responses to hypoxia. Proc Natl Acad Sci U S A. 2001 Jul 17; 98(15):8798-803. View Abstract
  88. Child health status, neurodevelopmental outcome, and parental satisfaction in a randomized, controlled trial of nitric oxide for persistent pulmonary hypertension of the newborn. Pediatrics. 2001 Jun; 107(6):1351-6. View Abstract
  89. Hypoxia extends the life span of vascular smooth muscle cells through telomerase activation. Mol Cell Biol. 2001 May; 21(10):3336-42. View Abstract
  90. Inhaled nitric oxide reduces the need for extracorporeal membrane oxygenation in infants with persistent pulmonary hypertension of the newborn. Crit Care Med. 2000 Nov; 28(11):3722-7. View Abstract
  91. Prevention of hypoxia-induced pulmonary hypertension by enhancement of endogenous heme oxygenase-1 in the rat. Circ Res. 2000 Jun 23; 86(12):1224-9. View Abstract
  92. Transgenic mice overexpressing heme oxygenase-1 (HO-1) in the lung are protected from development of hypoxia-induced pulmonary hypertension: Evidence of antiinflammatory effects of HO-1. Pediatric Research. 2000; 47(4):A385. View Abstract
  93. Heme oxygenase and pulmonary responses to hypoxia. Acta Haematologica. 2000; 103(1):A247. View Abstract
  94. Herbimycin A and geldanamycin inhibit the hypoxic induction of the vascular endothelial growth factor (VEGF) gene in pulmonary artery endothelial cells. Pediatric Research. 2000; 47(4):A380. View Abstract
  95. Extracellular acidosis induces heme oxygenase-1 (HO-1) gene expression in vascular smooth muscle cells. Pediatric Research. 2000; 47(4):A386. View Abstract
  96. The role of heme oxygenase-1 in the regulation of cardiomyocyte death during ischemia/reperfusion. Acta Haematologica. 2000; 103(1):A276. View Abstract
  97. Generation of a dominant-negative mutant of endothelial PAS domain protein 1 by deletion of a potent C-terminal transactivation domain. J Biol Chem. 1999 Oct 29; 274(44):31565-70. View Abstract
  98. Hypoxia induces severe right ventricular dilatation and infarction in heme oxygenase-1 null mice. J Clin Invest. 1999 Apr; 103(8):R23-9. View Abstract
  99. Functional analysis of endothelial PAS domain Protein 1: Generation of a dominant negative mutant by deleting C-terminal potent transactivation domain. Circulation. 1999; 100(18):A193. View Abstract
  100. Inhaled nitric oxide does not affect adenosine 5'-diphosphate-dependent platelet activation in infants with persistent pulmonary hypertension of the newborn. Pediatrics. 1998 Dec; 102(6):1390-3. View Abstract
  101. Hypoxic responses of vascular cells. Chest. 1998 Jul; 114(1 Suppl):25S-28S. View Abstract
  102. Carbon monoxide and nitric oxide suppress the hypoxic induction of vascular endothelial growth factor gene via the 5' enhancer. J Biol Chem. 1998 Jun 12; 273(24):15257-62. View Abstract
  103. Increased vascular endothelial growth factor production in the lungs of rats with hypoxia-induced pulmonary hypertension. Am J Respir Cell Mol Biol. 1998 Jun; 18(6):768-76. View Abstract
  104. Characterization of functional domains of endothelial PAS domain protein-1 and generation of a dominant negative mutant. Circulation. 1998. View Abstract
  105. Combination of inhaled nitric oxide with high frequency ventilation reduces the need for extracorporeal membrane oxygenation in infants with persistant pulmonary hypertension of the newborn: Results from a single center trial. Pediatric Research. 1998; 43(4):169A. View Abstract
  106. Activation of KDR/flk-1 promoter by endothelial PAS domain protein-1: Potential role of endothelial PAS domain protein-1 in endothelial cell differentiation. Circulation. 1998. View Abstract
  107. Shock. Manual of Neonatal Care (Cloherty JP and Stark AR, eds.). 1998; 171-173. View Abstract
  108. Carbon monoxide controls the proliferation of hypoxic vascular smooth muscle cells. J Biol Chem. 1997 Dec 26; 272(52):32804-9. View Abstract
  109. Improved oxygenation in a randomized trial of inhaled nitric oxide for persistent pulmonary hypertension of the newborn. Pediatrics. 1997 Nov; 100(5):E7. View Abstract
  110. Endothelin-1 production during the acute chest syndrome in sickle cell disease. Am J Respir Crit Care Med. 1997 Jul; 156(1):280-5. View Abstract
  111. Effect of inhaled nitric oxide on endothelin-1 and cyclic guanosine 5'-monophosphate plasma concentrations in newborn infants with persistent pulmonary hypertension. J Pediatr. 1997 Apr; 130(4):603-11. View Abstract
  112. Mechanisms by which oxygen regulates gene expression and cell-cell interaction in the vasculature. Kidney Int. 1997 Feb; 51(2):438-43. View Abstract
  113. Prevention of hypoxia-induced pulmonary hypertension by enhancement of endogenous heme oxygenase-1 in the rat. Pediatric Research. 1997; 41:A238. View Abstract
  114. Endogenous carbon monoxide regulates tube formation by human microvascular endothelial cells under high glucose. Circulation. 1997; 96(8):A4067. View Abstract
  115. Inhaled nitric oxide does not inhibit platelet activation in infants with persistent pulmonary hypertension of the newborn (PPHN). Pediatric Research. 1997; 41:A844. View Abstract
  116. Regulation of Carbon Monoxide Producation and Vascular Responses. Ketsuatsu - Japanese Journal of Blood Pressure. 1996; 3(2):260-268. View Abstract
  117. Improved oxygenation in a randomized trial of inhaled nitric oxide for PPHN. Pediatric Research. 1996; 39(4):A1498. View Abstract
  118. Endothelial cell expression of vasoconstrictors and growth factors is regulated by smooth muscle cell-derived carbon monoxide. J Clin Invest. 1995 Dec; 96(6):2676-82. View Abstract
  119. Basic fibroblast growth factor increases nitric oxide synthase production in bovine endothelial cells. Am J Physiol. 1995 Nov; 269(5 Pt 2):H1583-9. View Abstract
  120. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5' enhancer. Circ Res. 1995 Sep; 77(3):638-43. View Abstract
  121. Smooth muscle cell-derived carbon monoxide is a regulator of vascular cGMP. Proc Natl Acad Sci U S A. 1995 Feb 28; 92(5):1475-9. View Abstract
  122. Structural characterization and specificity of expression of E2F-5: a new member of the E2F family of transcription factors. Cell Mol Biol Res. 1995; 41(3):147-54. View Abstract
  123. Inhaled NO for PPHN: Basic Biology to Clinical Application (Fanaroff AA and Klaus MH, eds.). 1995 Year Book of Neonatal and Perinatal Medicine. 1995; xvii-xxxvi. View Abstract
  124. Increased epithelial cell expression of vascular endothelial growth factor (VEGF) in the lungs of animals with hypoxia-induced pulmonary hypertension. Am. J. Resp. Crit. Care Med. 1995; 151(4):A732. View Abstract
  125. Smooth muscle cell-derived carbon monoxide is a regulator of endothelial cell gene expression and cGMP content. Circulation. 1995; 92(8):110. View Abstract
  126. Persistent pulmonary hypertension of the newborn: Role of nitric oxide. J. Int. Care Medicine. 1995; 10:270-282. View Abstract
  127. Hypoxia upregulates the transcription of human vascular endothelial growth factor gene via a 28-bp enhancer. FASEB J. 1995; 9(3):A611. View Abstract
  128. Hypoxia increases cGMP levels in rat vascular smooth muscle cells via inducation of heme oxygenase-1. 67th Scientific Sessions of the American Heart Assocation, Dallas, TX. 1994. View Abstract
  129. Hypoxia inhibits expression of eNOS via transcriptional and posttranscriptional mechanisms. Am J Physiol. 1994 Nov; 267(5 Pt 2):H1921-7. View Abstract
  130. Hypoxia and endothelial-smooth muscle cell interactions in the lung. Am J Respir Cell Mol Biol. 1994 Oct; 11(4):373-4. View Abstract
  131. Transforming growth factor-beta 1, but not dexamethasone, down-regulates nitric-oxide synthase mRNA after its induction by interleukin-1 beta in rat smooth muscle cells. J Biol Chem. 1994 May 20; 269(20):14595-600. View Abstract
  132. Inhaled nitric oxide (NO) alters endogenous endothelin-1 (ET-1) and cGMP levels in newborns with persistent pulmonary hypertension (PPHN). Pediatric Research. 1994; 35(4):234A. View Abstract
  133. Nitric oxide regulates the expression of vasoconstrictors and growth factors by vascular endothelium under both normoxia and hypoxia. J Clin Invest. 1993 Jul; 92(1):99-104. View Abstract
  134. Hypoxia inhibits nitric oxide synthase (NOS) gene expression and nitric oxide (NO) production in endothelial cells. Pediatric Research. 1993; 33:51A. View Abstract
  135. Tumor necrosis factor increases transcription of the heparin-binding epidermal growth factor-like growth factor gene in vascular endothelial cells. J Biol Chem. 1992 May 15; 267(14):9467-9. View Abstract
  136. Hypoxic responses of the neonatal endothelium. Semin Perinatol. 1992 Apr; 16(2):140-6. View Abstract
  137. Feedback loops regulated the production of vasoactive agents by human endothelial cells. Pediatric Research. 1992; 31:46A. View Abstract
  138. Hypoxia induces endothelin gene expression and secretion in cultured human endothelium. J Clin Invest. 1991 Sep; 88(3):1054-7. View Abstract
  139. Shock. Manual of Neonatal Care (Cloherty JP and Stark AR, eds.). 1991; 68-71. View Abstract
  140. Molecular mechanisms contrbuting to hypoxic vasoconstriction. Pediatric Research. 1991; 29:255A. View Abstract
  141. Oxygen tension regulates the expression of the platelet-derived growth factor-B chain gene in human endothelial cells. J Clin Invest. 1990 Aug; 86(2):670-4. View Abstract
  142. Fetal rat lung fibroblasts produce a TGF beta homolog that blocks alveolar type II cell maturation. Dev Biol. 1990 May; 139(1):35-41. View Abstract
  143. Molecular mechanisms contributing to vaso-occlusion in sickle cell disease. Blood. 1990; 76:10S1. View Abstract
  144. Platelet-derived growth factor production by human umbilical vein endothelial cells is regulated by basic fibroblast growth factor. J Biol Chem. 1989 Mar 15; 264(8):4456-9. View Abstract
  145. Hypoxia stimulates platelet-derived growth factor (PDGF) production by human umbilical vein endothelial cells (HUVEC). Pediatric Research. 1989; 25:54A. View Abstract
  146. Regulation of platelet-derived growth factor (PDGF) gene expression by basic fibroblast growth factor (bFGF) in human umbilical vein endothelial cells. Pediatric Research. 1988; 23:245A. View Abstract
  147. Endothelial cells synthesize basic fibroblast growth factor and transforming growth factor beta. Growth Factors. 1988; 1(1):7-17. View Abstract
  148. Immortalization of human endothelial cells by murine sarcoma viruses, without morphologic transformation. J Cell Physiol. 1988 Jan; 134(1):47-56. View Abstract
  149. Increases in the 35kDa surfactant-associated protein and its mRNA following in vivo dexamethasone treatment of fetal and neonatal rats. Electrophoresis. 1987; 8:235-238. View Abstract
  150. Primary translation products, biosynthesis, and tissue specificity of the major surfactant protein in rat. J Biol Chem. 1986 Jan 15; 261(2):828-31. View Abstract
  151. Developmental profile of surgactant associated protein (Apoprotein A) in the rat lung. Eleventh Annual New England Conference on Perinatal Resesarch. 1985. View Abstract

Contact Stella Kourembanas

Print Profile